ClosedResearch announcementOpportunity HT942526ALSRPCOBA

DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award

Defense Health Agency Contracting Activity - DHACA · Department of Defense

At a glance

DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award is a closed federal grant opportunity from the Defense Health Agency Contracting Activity - DHACA (Department of Defense). The application deadline was September 30, 2026. Total estimated funding is $7M across about 7 awards. The notice is unrestricted by applicant type, subject to any clarifications in the notice. Cost sharing is not required. It is funded under Assistance Listing 12.420 (Military Medical Research and Development).

Summary assembled from the official notice's fields. The official notice governs.

Key facts

May 4, 2026Posted
Sep 30, 2026Application deadline
Oct 30, 2026Archivednext date

Posted: May 4, 2026
Close date: Sep 30, 2026
Archive date: Oct 30, 2026
Award floor: Not specified
Award ceiling: Not specified
Est. total funding: $7,000,000
Implied average award: $1,000,000 calculated
Expected awards: 7
Cost sharing: Not required
Funding instrument: Grant
Opportunity category: Discretionary

Typical awards for this program (SAM.gov listing for ALN 12.420, not this notice): This Assistance Listing supports approximately 30 or more programs each year. Overall, awards are expected to range from $100,000 to $20M (consortium) depending on the funding priorities, anticipated number of awards, and project activity/scope within each program for an award period, on average, of 3 to 4 years. The maximum award amount, if any, is specified in each Program Announcement or Broad Agency Announcement.

Implied average = estimated total funding ÷ expected number of awards, calculated by GrantsJunction. Actual awards vary.

Who can apply

Unrestricted (any entity type)

Can your organization apply?

A quick check against the listed applicant types — other requirements in the notice still apply.

Based on the published notice. Review the official notice for complete eligibility requirements.

What it funds

Official synopsis as published by the agency, formatted for readability.

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in amyotrophic lateral sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients.

Distinctive Features: To meet the intent of the funding opportunity, applications may address clinical biomarkers and/or clinical outcomes. This may include the identification, development, and/or validation of promising biomarkers for ALS, which may include, but are not limited to susceptibility/risk, diagnostic, monitoring/disease progression, prognostic, predictive, response, or safety biomarkers. Clinical Outcomes projects may focus on the identification, development, and/or validation of clinician-, observer-, or patient-reported, and/or performance outcome measures for ALS. Projects may include the optimization of current outcome measures already in use.

Applications may utilize digital health measures, including wearable devices, smart-phone sensors, video or voice recordings, imaging studies, or other devices which record disease-relevant physiological data and/or outcomes.

Community Collaboration is an important element of the FY26 ALSRP COBA. Applicants will be expected to articulate how the proposed research question or study design was informed by the

ALS lived experience community.

Full announcement & documents

The full announcement has the complete rules — page limits, required attachments, evaluation criteria and any letter-of-intent dates. Files download directly from Grants.gov.

FY26 ALSRP COBA Program AnnouncementFull Announcement · HT942526ALSRPCOBA_GG.pdfPDF · 724 KB

Assistance Listing

What is an ALN?

12.420Military Medical Research and DevelopmentProgram →

Reported obligations under ALN 12.420

Historical data · not a prediction

FY24

$1.48B

FY25

$1.2B

FY26

— est.

Source: SAM.gov Assistance Listing 12.420. Program-wide totals, not awards from this specific opportunity.

Agency contact (as published)

Jamie Shortall Grant Officer
help@eBRAP.org
301-619-2393

Quick answers

Who is eligible to apply for “DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award”?

The notice lists eligibility as unrestricted — open to any type of entity — subject to clarifications in the notice's additional eligibility information.

How much funding is available through “DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award”?

Per the notice, total estimated program funding is $7,000,000 and the agency expects to make about 7 awards.

How do I apply for “DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award”?

Applications are submitted through the official source, not through GrantsJunction. Open the official notice on Grants.gov (opportunity HT942526ALSRPCOBA), and review the full announcement and application package. Organizations applying through Grants.gov generally need an active SAM.gov registration and a Grants.gov account, which can take several weeks to set up.

Matched on shared Assistance Listings, agency, categories and eligible applicant types.

Closes in 6 daysResearchALN 12.420